+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Gastrointestinal Diseases Drug Development Pipeline Review, 2018

  • ID: 4727292
  • Report
  • Region: Global
  • 98 Pages
  • GBI Research
1 of 4

FEATURED COMPANIES

  • Avexegen Therapeutics Inc
  • Daewon Pharm Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Medicago Inc
  • Ology Bioservices Inc
  • Recce Ltd
  • MORE

Summary
Gastroenteritis is an infection of the gut. Symptoms include stomach pain, cramping, fever, nausea, and a headache. Causes of gastroenteritis include contaminated food or water and contact with someone who has the virus. Treatment includes antibiotics, anti-emetic and anti-diarrheal medications. There are 12 products in development for this indication.

Enterocolitis is an inflammation of the large and small intestines. Symptoms include fever, abdominal swelling, nausea, diarrhea, rectal bleeding and sluggishness. Causes of enterocolitis include inflammation of the intestinal tissues, delayed gastric emptying, abdominal wall erythema, apnea, sepsis and cardiovascular collapse. Treatment includes antibiotics. There are eight products in development for this indication.

Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, naproxen on long periods of consumption, excess intake of alcohol, Helicobacter pylori infection, certain autoimmune disorders, bile reflux, substance abuse (cocaine), consumption of corrosive or caustic substances such as poisons, extreme stress, viral infections and trauma.

The symptoms of gastritis may include loss of appetite, nausea and vomiting, abdominal pain and black stools. Treatment includes use of antacids, histamine 2 (H2) antagonists and proton pump inhibitors. There are 11 products in development for this indication.

Peritonitis is inflammation of the peritoneum. There are two types of peritonitis. Spontaneous bacterial peritonitis is the result of an infection of the fluid in the peritoneal cavity. Secondary peritonitis is usually due to an infection that has spread from the digestive tract. Symptoms include abdominal bloating, nausea and vomiting, diarrhea, fatigue, fever and chills. Treatment includes antibiotics. There are seven products in development for this indication.

Molecular targets in development for gastrointestinal diseases include toll-like receptors, interleukin receptors and bacterial proteins. Companies operating in this pipeline space include Kyowa Hakko Kirin, RedHill Biopharma and GlaxoSmithKline.

This report “Gastrointestinal Diseases Drug Development Pipeline Review, 2018” provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for gastroenteritis, enterocolitis, gastritis and peritonitis, and features dormant and discontinued products.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Avexegen Therapeutics Inc
  • Daewon Pharm Co Ltd
  • Kyowa Hakko Kirin Co Ltd
  • Medicago Inc
  • Ology Bioservices Inc
  • Recce Ltd
  • MORE

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Gastrointestinal Diseases Report Coverage
2.2 Gastroenteritis - Overview
2.3 Enterocolitis - Overview
2.4 Gastritis - Overview
2.5 Peritonitis - Overview

3 Therapeutics Development
3.1 Gastroenteritis
3.2 Enterocolitis
3.3 Gastritis
3.4 Peritonitis

4 Therapeutics Assessment
4.1 Gastroenteritis
4.2 Enterocolitis
4.3 Gastritis
4.4 Peritonitis

5 Companies Involved in Therapeutics Development
5.1 Gastroenteritis
5.2 Enterocolitis
5.3 Gastritis
5.4 Peritonitis

6 Dormant Projects
6.1 Gastroenteritis
6.2 Enterocolitis
6.3 Gastritis
6.4 Peritonitis

7 Discontinued Products
7.1 Gastroenteritis

8 Product Development Milestones
8.1 Gastroenteritis
8.2 Enterocolitis
8.3 Gastritis
8.4 Peritonitis

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

List of Tables
Table 1: Number of Products under Development for Gastroenteritis
Table 2: Number of Products under Development by Companies, Gastroenteritis
Table 3: Number of Products under Development by Universities/Institutes, Gastroenteritis
Table 4: Products under Development by Companies, Gastroenteritis
Table 5: Products under Development by Universities/Institutes, Gastroenteritis
Table 6: Number of Products under Development for Enterocolitis
Table 7: Number of Products under Development by Companies, Enterocolitis
Table 8: Number of Products under Development by Universities/Institutes, Enterocolitis
Table 9: Products under Development by Companies, Enterocolitis
Table 10: Products under Development by Universities/Institutes, Enterocolitis
Table 11: Number of Products under Development for Gastritis
Table 12: Number of Products under Development by Companies, Gastritis
Table 13: Products under Development by Companies, Gastritis
Table 14: Number of Products under Development for Peritonitis
Table 15: Number of Products under Development by Companies, Peritonitis
Table 16: Products under Development by Companies, Peritonitis
Table 17: Number of Products by Stage and Target, Gastroenteritis
Table 18: Number of Products by Stage and Mechanism of Action, Gastroenteritis
Table 19: Number of Products by Stage and Route of Administration, Gastroenteritis
Table 20: Number of Products by Stage and Molecule Type, Gastroenteritis
Table 21: Number of Products by Stage and Target, Enterocolitis
Table 22: Number of Products by Stage and Mechanism of Action, Enterocolitis
Table 23: Number of Products by Stage and Route of Administration, Enterocolitis
Table 24: Number of Products by Stage and Molecule Type, Enterocolitis
Table 25: Number of Products by Stage and Target, Gastritis
Table 26: Number of Products by Stage and Mechanism of Action, Gastritis
Table 27: Number of Products by Stage and Route of Administration, Gastritis
Table 28: Number of Products by Stage and Molecule Type, Gastritis
Table 29: Number of Products by Stage and Target, Peritonitis
Table 30: Number of Products by Stage and Mechanism of Action, Peritonitis
Table 31: Number of Products by Stage and Route of Administration, Peritonitis
Table 32: Number of Products by Stage and Molecule Type, Peritonitis
Table 33: Gastroenteritis - Pipeline by Kyowa Hakko Kirin Co Ltd
Table 34: Gastroenteritis - Pipeline by Medicago Inc
Table 35: Gastroenteritis - Pipeline by Ology Bioservices Inc
Table 36: Gastroenteritis - Pipeline by RedHill Biopharma Ltd
Table 37: Gastroenteritis - Pipeline by Regeneron Pharmaceuticals Inc
Table 38: Gastroenteritis - Pipeline by Takeda Pharmaceutical Co Ltd
Table 39: Gastroenteritis - Pipeline by UMN Pharma Inc
Table 40: Gastroenteritis - Pipeline by Vaxart Inc
Table 41: Enterocolitis - Pipeline by Avexegen Therapeutics Inc
Table 42: Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB
Table 43: Enterocolitis - Pipeline by Leadiant Biosciences Inc
Table 44: Enterocolitis - Pipeline by ProMetic Life Sciences Inc
Table 45: Gastritis - Pipeline by BCWorld Pharm Co Ltd
Table 46: Gastritis - Pipeline by Daewon Pharm Co Ltd
Table 47: Gastritis - Pipeline by Daewoong Pharmaceutical Co Ltd
Table 48: Gastritis - Pipeline by Kyowa Hakko Kirin Co Ltd
Table 49: Gastritis - Pipeline by Recce Ltd
Table 50: Gastritis - Pipeline by RedHill Biopharma Ltd
Table 51: Gastritis - Pipeline by Sequella Inc
Table 52: Peritonitis - Pipeline by GlaxoSmithKline Plc
Table 53: Peritonitis - Pipeline by Nosopharm SAS
Table 54: Peritonitis - Pipeline by Oncodesign SA
Table 55: Peritonitis - Pipeline by SynAct Pharma AB
Table 56: Gastroenteritis - Dormant Projects
Table 57: Enterocolitis - Dormant Projects
Table 58: Gastritis - Dormant Projects
Table 59: Peritonitis - Dormant Projects
Table 60: Gastroenteritis - Discontinued Products

List of Figures
Figure 1: Number of Products under Development for Gastroenteritis
Figure 2: Number of Products under Development by Companies, Gastroenteritis
Figure 3: Number of Products under Development by Universities/Institutes, Gastroenteritis
Figure 4: Number of Products under Development for Enterocolitis
Figure 5: Number of Products under Development by Companies, Enterocolitis
Figure 6: Number of Products under Development for Gastritis
Figure 7: Number of Products under Development by Companies, Gastritis
Figure 8: Number of Products under Development for Peritonitis
Figure 9: Number of Products under Development by Companies, Peritonitis
Figure 10: Number of Products by Targets, Gastroenteritis
Figure 11: Number of Products by Stage and Targets, Gastroenteritis
Figure 12: Number of Products by Mechanism of Actions, Gastroenteritis
Figure 13: Number of Products by Stage and Mechanism of Actions, Gastroenteritis
Figure 14: Number of Products by Routes of Administration, Gastroenteritis
Figure 15: Number of Products by Stage and Routes of Administration, Gastroenteritis
Figure 16: Number of Products by Molecule Types, Gastroenteritis
Figure 17: Number of Products by Stage and Molecule Types, Gastroenteritis
Figure 18: Number of Products by Targets, Enterocolitis
Figure 19: Number of Products by Stage and Targets, Enterocolitis
Figure 20: Number of Products by Mechanism of Actions, Enterocolitis
Figure 21: Number of Products by Stage and Mechanism of Actions, Enterocolitis
Figure 22: Number of Products by Stage and Routes of Administration, Enterocolitis
Figure 23: Number of Products by Molecule Types, Enterocolitis
Figure 24: Number of Products by Stage and Molecule Types, Enterocolitis
Figure 25: Number of Products by Targets, Gastritis
Figure 26: Number of Products by Stage and Targets, Gastritis
Figure 27: Number of Products by Mechanism of Actions, Gastritis
Figure 28: Number of Products by Stage and Mechanism of Actions, Gastritis
Figure 29: Number of Products by Routes of Administration, Gastritis
Figure 30: Number of Products by Stage and Routes of Administration, Gastritis
Figure 31: Number of Products by Molecule Types, Gastritis
Figure 32: Number of Products by Stage and Molecule Types, Gastritis
Figure 33: Number of Products by Targets, Peritonitis
Figure 34: Number of Products by Stage and Targets, Peritonitis
Figure 35: Number of Products by Mechanism of Actions, Peritonitis
Figure 36: Number of Products by Stage and Mechanism of Actions, Peritonitis
Figure 37: Number of Products by Routes of Administration, Peritonitis
Figure 38: Number of Products by Stage and Routes of Administration, Peritonitis
Figure 39: Number of Products by Molecule Types, Peritonitis
Figure 40: Number of Products by Stage and Molecule Types, Peritonitis

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Avexegen Therapeutics Inc
  • BCWorld Pharm Co Ltd
  • Daewon Pharm Co Ltd
  • Daewoong Pharmaceutical Co Ltd
  • GlaxoSmithKline Plc
  • Infant Bacterial Therapeutics AB
  • Kyowa Hakko Kirin Co Ltd
  • Leadiant Biosciences Inc
  • Medicago Inc
  • Nosopharm SAS
  • Ology Bioservices Inc
  • Oncodesign SA
  • ProMetic Life Sciences Inc
  • Recce Ltd
  • RedHill Biopharma Ltd
  • Regeneron Pharmaceuticals Inc
  • Sequella Inc
  • SynAct Pharma AB
  • Takeda Pharmaceutical Co Ltd
  • UMN Pharma Inc
  • Vaxart Inc
Note: Product cover images may vary from those shown
Adroll
adroll